文献速递艾滋病与性传播感染病毒性肝炎

荷兰无限制获取直接抗病毒药物后HIV/HCV合并感染患者治疗 uptake 高

High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands.
PubMed 文献 · Clin Infect Dis · 2018-01-01

荷兰自2015年11月起无限制提供直接抗病毒药物(DAA),基于ATHENA HIV观察队列分析HIV/HCV合并感染者的治疗 uptake 与结局。在1471例符合条件患者中,87%曾启动HCV治疗,76%获治愈,6% DAA治疗结果待定。作者认为这种快速扩大治疗可能有助于未来在该人群中消除HCV。

要点

  • 在1471例HIV/HCV合并感染者中,87%(1284例)曾启动HCV治疗,76%(1124例)获治愈。
  • 6%(92例)DAA治疗结果待定;187例从未启动治疗,14例DAA失败,54例聚乙二醇干扰素α方案失败。
  • 在男男性行为者中,83%(844/1022)获治愈,6%(66/1022)DAA治疗结果待定。

核心结论

  • 无限制DAA可及15个月后,荷兰大多数HIV/HCV合并感染者已获HCV治愈(76%)或正在等待DAA治疗结果(6%)。
  • 作者认为这种快速治疗扩大可能有助于未来在这些患者中消除HCV。

研究设计与样本

  • 数据来自ATHENA HIV观察队列,该队列纳入自1998年以来注册的超过98%的HIV感染者。
  • 纳入标准为曾有一次HCV RNA阳性结果、无自发清除、且已知仍在接受照护;若患者多次治疗,仅纳入最近一次治疗发作的数据。
  • 数据更新至2017年2月,并于2017年4月向每个治疗中心查询DAA治疗及获得持续病毒学应答的数据更新。

主要发现

  • 在23574例曾链接照护的HIV感染者中,1471例HCV合并感染者符合纳入标准(69%为男男性行为者,15%为[既往]注射毒品者,15%为其他HIV传播途径)。
  • 1471例中,87%(1284例)在2000年至2017年间曾启动HCV治疗,76%(1124例)HCV感染获治愈,6%(92例)DAA治疗结果待定。
  • 在男男性行为者中,83%(844/1022)HCV感染获治愈,6%(66/1022)DAA治疗结果待定。
  • 总体而言,187例从未启动治疗,14例DAA治疗失败,54例聚乙二醇干扰素α为基础方案治疗失败。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since November 2015. We analyzed the nationwide hepatitis C virus (HCV) treatment uptake among patients coinfected with human immunodeficiency virus (HIV) and HCV. METHODS: Data were obtained from the ATHENA HIV observational cohort in which >98% of HIV-infected patients ever registered since 1998 are included. Patients were included if they ever had 1 positive HCV RNA result, did not have spontaneous clearance, and were known to still be in care. Treatment uptake and outcome were assessed. When patients were treated more than once, data were included from only the most recent treatment episode. Data were updated until February 2017. In addition, each treatment center was queried in April 2017 for a data update on DAA treatment and achieved sustained virological response. RESULTS: Of 23574 HIV-infected patients ever linked to care, 1471 HCV-coinfected patients (69% men who have sex with men, 15% persons who [formerly] injected drugs, and 15% with another HIV transmission route) fulfilled the inclusion criteria. Of these, 87% (1284 of 1471) had ever initiated HCV treatment between 2000 and 2017, 76% (1124 of 1471) had their HCV infection cured; DAA treatment results were pending in 6% (92 of 1471). Among men who have sex with men, 83% (844 of 1022) had their HCV infection cured, and DAA treatment results were pending in 6% (66 of 1022). Overall, 187 patients had never initiated treatment, DAAs had failed in 14, and a pegylated interferon-alfa-based regimen had failed in 54. CONCLUSIONS: Fifteen months after unrestricted DAA availability the majority of HIV/HCV-coinfected patients in the Netherlands have their HCV infection cured (76%) or are awaiting DAA treatment results (6%). This rapid treatment scale-up may contribute to future HCV elimination among these patients.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Boerekamps A, Newsum AM, Smit C, et al. High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands. Clin Infect Dis. 2018. PMID: 29186365. doi:10.1093/cid/cix1004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。